Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044644 | 1.00 | RELA (0.67) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL23158820 | 0.87 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700055 | 0.87 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700056 | 0.87 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL31317665 | 0.87 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700797 | 0.82 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700798 | 0.82 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL257114 | 0.82 | RELA (0.69) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL7194475 | 0.82 | RELA (0.69) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL14401251 | 0.82 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | claimed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1931425-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-5053070-A | PYRIMIDINE DERIVATIVES, PREPARATION PROCESSES THEREOF, HERBICIDE CONTAINING THE SAME, AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME ALONG WITH OTHER ACTIVE INGREDIENT | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4986846-A | PRE-AND POSTEMERGENCE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0374839-A1 | 2-(4,6-Dimethoxy-2-pyrimidinyloxy)benzaldoximes, preparation processes thereof, herbicides containing the same, and herbicidal compositions containing the same along with other active ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RELA 1066/4885NFE2L2 2330/4885CYP19A1 3397/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RELA 1066/4885NFE2L2 2330/4885CYP19A1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.